Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Impact of Food on Blood Sugar in People With Type 2 Diabetes (REACT2)

This study has been completed.
International Diabetes Center at Park Nicollet
Information provided by (Responsible Party):
HealthPartners Institute Identifier:
First received: November 5, 2010
Last updated: November 30, 2015
Last verified: April 2013

This study will record the impact of food on blood glucose levels using continuous glucose monitoring (CGM).

The investigators think the impact will improve as medication doses are adjusted. The investigators also think that the impact will differ depending on the type of medication taken.

Type 2 Diabetes

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Evaluation of the Glycemic Impact of Food in Patients With Type 2 Diabetes Taking Glargine and/or Exenatide

Resource links provided by NLM:

Further study details as provided by HealthPartners Institute:

Primary Outcome Measures:
  • 4-hour glycemic response at 3 time points [ Time Frame: 4 hours ]
    The four-hour glycemic response includes: four-hour post-meal area under the median interstitial glucose curve, post-meal interstitial glucose peak, time to peak, time to return to pre-prandial level (to within 10% of baseline with a maximum of the 4-hour post-meal fast), difference between peak and baseline, average rate of change in interstitial glucose across the 4 hour post-meal period, and percent of the 4-hour post-meal glucose readings >180 mg/dL.

Enrollment: 46
Study Start Date: November 2010
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Glargine Group
After baseline titration of metformin, this group will take glargine along with metformin.
Exenatide Group
After baseline titration of metformin, this group will take exenatide along with metformin.
Glargine and Exenatide Group
After baseline titration of metformin, this group will take glargine and exenatide along with metformin.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participants in Clinical Trials Study NCT01089569

Inclusion Criteria:

  • Study participants who are consented for the primary study and have not yet done the baseline CGM data collection at week -2-0.

Exclusion Criteria:

  • Study participants who are unable to complete the baseline CGM data collection at week -2-0.
  • Study participants who are allergic to or have a food intolerance to any of the foods in the fixed meal
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01237314

United States, Minnesota
International Diabetes Center
Minneapolis, Minnesota, United States, 55416
Sponsors and Collaborators
HealthPartners Institute
International Diabetes Center at Park Nicollet
Principal Investigator: Maggie Powers, PhD International Diabetes Center at Park Nicollet
Principal Investigator: Alice Shapiro, PhD International Diabetes Center at Park Nicollet
  More Information

Responsible Party: HealthPartners Institute Identifier: NCT01237314     History of Changes
Other Study ID Numbers: 04037-10-C
Study First Received: November 5, 2010
Last Updated: November 30, 2015

Keywords provided by HealthPartners Institute:
type 2 diabetes
glycemic impact of food
continuous glucose monitoring

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on May 25, 2017